Council of Scientific and Industrial Research

Bikash Chandra Pal

Samir Bhattacharya

Santu Bandyopadhyay

Keshab Chandra Roy

Mitali Ray

Goutam Banerjee

Tanusree Biswas

Ranjan Bhadra

Krishna Das

Mitali Roy

Samir Bhattacharaya

Aditya Konar

Mohua Mukherjee

Arun Bandyopadhyay

Malabika Datta

Sib Sankar Roy

Debashis Mitra

Bir Bhanu Giri

Syed Nazrul Kabir

Santu Bandopadhyay

Heramba Nanda Ray

Gautam Bandyopadhyay

Debleena Dey

Swapan Kumar Mandal

Tanushree Biswas

Acaciaside-B (Ac-B) has emerged as a prospective candidate molecule for prevention of HIV infection along with potential for use as/in vaginal contraceptive/formulation. It possesses anti-HIV property at a tolerably low concentration, is non-mutagenic and does not harm the niche of. Thus Ac-B appears to be a superior ingredient for formulations of a chemical barrier against HIV-1 infection wherein its spermicidal property is superfluous.

Pharmaceutical composition having virucidal and spermicidal activity

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof

The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts ofor any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

Synergistic composition for treating leukemia

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water: methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.

Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant Pueraria tuberosa

This invention relates to use of betel leaf extract to induce IFN&#x3b3; from human peripheral blood mononuclear cells and as a Thtype immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18&#x2013;48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&#x3b3; specific known primers, and enhancement of IFN&#x3b3; as reflected by IFN&#x3b3; specific band.

Use of betel leaf extract to induce IFN-gamma production from human peripheral blood T cells and as a Th1 type immunomodulator

A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia byleaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts ofto treat CD33+ AML and CML with a simplified method of isolation of active components from all plant parts ofpossessing biological activities relevant to the treatment of CD33+ AML and CML.

Herbal-based composition for treating acute and chronic myeloid leukemia

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with the fractions used both individually, and in combination, and a composition including the fraction nos. 1 and 9.

This invention relates to an herbal composition for the treatment and remedy of bronchial respiratory difficulties, more particularly this invention describes the process of separation, physicochemical characterization and biological response evaluation of active components obtained from extracts of any plant parts including leaves, barks, roots and seeds of plants and in order to establish their role on the treatment and remedy of bronchial respiratory troubles.

HERBAL COMPOSITION OF BLEND OF ACTIVE COMPONENTS PREPARED FROM MURRYA KOENIGII AND PIPER BETLE USEFUL FOR BLOCKING OF 5 LIPOXYGENASE ACTIVITY LEADING TO THE INHIBITION OF LEUKOTRIENE SYNTHESIS, SUPPRESSION OF INTERLEUKIN-4 PRODUCTION, AND ENHANCEMENT OF GAMMA INTERFERON RELEASE

The invention relates to a novel composition containing an extract obtained from the plant and useful for the treatment or providing relief from acute asthma, and a process for the preparation of a lyophilized extract containing active principles of the plant and a method for the treatment of asthma.

Herbal composition for treating asthma

This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Anti-leishmanial activity of betel leaf extract

This invention relates to use of betel leaf extract to induce IFN&ggr; from human peripheral blood mononuclear cells and as a Th type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&ggr; specific known primers, and enhancement of IFN&ggr; as reflected by IFN&ggr; specific band.

A pharmaceutical formulation is provided which is useful as a leukotrine synthesis and IL4 inhibitor and as a Th1 immunomodulator. The formulation comprises an effective amount of a combination of extracts and lyophilized extracts of and . The formulation can be formulated with pharmaceutically acceptable carriers. The formulation can be used in a method of treating humans for respiratory conditions.

Growing community of inventors

Calcutta, India

Bikash Chandra Pal